Objective: Many evidences suggested that impairment of glutathione-dependent system is observed in the brain of schizophrenic patients. GSH is an important substrate of glutathione peroxidase (GPx). It is recognized that selenium-dependent GPx (GPx-1) out of GPx isozymes provides a first line of defense against peroxides. Thus, we investigated in the present study a role of GPx-1 gene in schizophrenia-like psychosis induced by phencyclidine (PCP) in mice. Method: GPx-1 knock-out (KO)-, wild-type (WT)-, GPx-1 overexpressing transgenic (Tg)-and non-Tg-mice were received PCP (10 mg/kg/day, s.c.) for consecutive 14 days. Novel object recognition-, forced swimming-, and social interaction-tests were performed 7 days after withdrawal from PCP. Behavioral sensitization to an acute challenge of PCP (3 mg/kg, s.c.) was also evaluated. We examined Nrf-2-dependent GSH-synthetic process in the prefrontal cortex and hippocampus. Result: PCP-induced behavioral side effects were more pronounced in the GPx-1 KO than those in WT mice, and they were less pronounced in GPx-1 Tg than those in non-Tg mice. Moreover, PCP treatment significantly reduced GSH level, and increased oxidative burdens in prefrontal cortex as compared to those in hippocampus. Treatment with PCP resulted in a significant increase in nuclear translocation of Nrf2, Nrf2 DNA binding activity, and γ-glutamylcysteine modifier subunit (GCLm) mRNA expression in WT or non-Tg mice. These inductions were not observed in GPx1 KO mice. Further, this Nrf-2 dependent GSH synthetic system was more pronounced in GPx-1 Tg than non-Tg mice. Conclusion: Our results suggest that GPx-1 gene is a potential protective factor in response to schizophrenia-like psychosis induced by PCP in mice [This study was supported by a grant (14182MFDS979) from the Korea Food and Drug Administration, Republic of Korea].
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Abstract
Objective: Paliperidone exhibits protective effects for liver, but the association between paliperidone use and the risk of severe hepatic outcome in schizophrenia patients with viral hepatitis is unknown. This population-based study is aimed to assess the incidence and risk of severe hepatic outcome among schizophrenia patients with viral hepatitis who received paliperidone. Methods: Using a nationwide database, the Taiwan National Health Insurance Research Database, subjects who had first been diagnosed with schizophrenia between 2007 and 2013 were identified. The schizophrenia patients with viral hepatitis receiving paliperidone were designated as the paliperidone group. A 1:2 ratio was used to select age-, gender-, and indexyear -matched control without paliperidone use. Patients who had severe hepatic outcome before enrollment were excluded. The 2 cohorts were observed until December 31, 2013. The primary endpoint was occurrence of severe hepatic outcome including liver failure, liver decompensation, liver transplantation, and liver cancer. Results: Among 953 newly diagnosed schizophrenia patients with viral hepatitis, we identified 134 patients with paliperidone use, and 268 matched patients without paliperidone use between January 2007 and December 2013. Of the 402 patients, 22 (5.47%) suffered from severe hepatic outcome during a mean follow-up period of 6.639 years, including 2 (1.49%) from the paliperidone cohort and 20 (7.46%) from the control group. In schizophrenia patients with viral hepatitis, the Cox multivariate proportional hazards analysis showed that the risk decreased with paliperidone use 0.1938 (95% confidence interval (CI), 0.0802 to 0.4681; p = 0.0135). Conclusions: Paliperidone use was associated with a reduced risk of severe hepatic outcome among schizophrenia patients with viral hepatitis.
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Quality of Life in patients with schizophrenia or bipolar disorder receiving long-acting antipsychotics
Shih-Ku Lin, Taiepi City Hospital and Psychiatric Center, Taiwan
Abstract Objective: Long-acting injectable antipsychotic (LAI) provides a potential solution to overcome poor adherence to medication in Abstracts | 39 patients with schizophrenia or bipolar disorder. Quality of life (QoL) is the general feelings of well-being of individuals. In this study, we measured the QoL in patients with schizophrenia or bipolar disorder who were receiving LAI treatment. Methods: 434 patients with schizophrenia and 42 patients with bipolar disorder received LAI treatment for at least 6 months regularly at Taipei City Psychiatric Center were administered with Brief World Health Organization's Quality of Life (WHOQoL), Chinese Health Questionnaire (CHQ), Subjective Well-being under Neuroleptics (SWN) and Social Performance scale (PSP) in a cross-sectional interview. Results: The duration of LAI treatment was 8.6 ± 8.9 years for schizophrenia and 5.5 ± 7.5 years for bipolar disorder, with total scores of WHOQoL 50.4 ± 8.9 and 52.1 ± 8.9, respectively (Norm: 56.1 in Taiwan). There was no difference in WHOQOL, CHQ between the two groups, while the bipolar patients had slightly higher SWN (81.8 ± vs 13.278.1 ± 12.2, P= 0.060) and significant PSP scores (74.6 ± 5.8 vs 71.0 ± 5.9, P<0.001). The Frequency of hospitalization (times/year) were significantly decreased after LAI treatment in schizophrenia (0.26 ± 0.42 to 0.09 ± 0.24) and bipolar disorder (0.56 ± 0.67 to 0.15 ± 0.39). Conclusions: LAI treatment can efficaciously prevent the relapse of psychotic or mood episodes in patients with poor adherence to medications. Patients with bipolar disorders reported a slightly higher satisfaction, in terms of SWN and PSP, but not QoL and CHQ, than patients with schizophrenia. These results suggest that patients with schizophrenia or bipolar disorder can have an acceptable level of QoL when they are under a regular adherence to medications.
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Treatment successful rate and efficacy of Paliperidone ER in patients with acute schizophrenia Yi-hsing Chen, Chang Bing Show Chwan Memorial Hospital, Taiwan Abstract Objective: The treatment successful rate is one of the major concerns in acute phase of schizophrenia. This study aimed to evaluate the treatment successful rate and efficacy of Paliperidone ER in acute schizophrenia and schizoaffective disorder patients. Method: Retrospective 12 months patients who received Paliperidone ER treatment after admitted to acute ward as first-line antipsychotic were enrolled in this study. The primary endpoint was Clinical Global Impression-Severity (CGI-S) score. Secondary endpoints included dosage distributed rate of Paliperidone ER while admission and discharged, combined medication (anticholinergics) situation, duration dates of admission. Treatment successful was defined to change CGI-S score more than 1 point. Combined other antipsychotics were not allowed. . Results: 40 Patients enrolled. Treatment successful rate is 86%. Mean CGI-S score changed from 4.77 to 3.2. Admission dosage distributed rate is 9mg 39%; 12mg 33%, discharge dosage distributed rate is 9mg 28%; 12mg 44%. Anticholinergics were frequently needed to prevent EPS symptoms, but additional dosage didn't need. Average duration date of admission is 33.6 days.
Conclusion:
In acute ward we need to control patient's symptoms in short time. We may not have too much time to try the second antipsychotic during admission. In this study we find that Paliperidone ER can offer enough successful rate when first-line use. Maybe start with optimal dosage (9~12mg) can be more ensured highest successful treatment rate, and seems safe when higher dosage usage. We expect Paliperidone ER can effectively help patient improve during acute stage schizophrenia.
